Omnicell, Inc. (NASDAQ:OMCL) EVP Dan S. Johnston sold 14,613 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares of the company’s stock, valued at $2,085,520.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Omnicell, Inc. (OMCL) traded up $0.30 during midday trading on Friday, hitting $48.25. 294,052 shares of the company’s stock were exchanged, compared to its average volume of 255,265. Omnicell, Inc. has a fifty-two week low of $31.85 and a fifty-two week high of $55.40. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business had revenue of $186.78 million during the quarter, compared to the consensus estimate of $192.45 million. During the same quarter last year, the firm earned $0.40 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. sell-side analysts anticipate that Omnicell, Inc. will post 0.12 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/17/omnicell-inc-omcl-evp-sells-698647-53-in-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Turner Investments LLC bought a new position in shares of Omnicell during the second quarter valued at approximately $181,000. Flinton Capital Management LLC grew its holdings in shares of Omnicell by 74.6% during the second quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock valued at $182,000 after buying an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in shares of Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after buying an additional 1,830 shares during the last quarter. Marco Investment Management LLC purchased a new stake in shares of Omnicell during the third quarter valued at approximately $231,000. Finally, Sei Investments Co. grew its holdings in shares of Omnicell by 36.4% during the second quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock valued at $200,000 after buying an additional 1,242 shares during the last quarter. 98.64% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently issued reports on OMCL. Benchmark Co. increased their price target on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and issued a $40.00 price target on shares of Omnicell in a research note on Sunday, July 30th. Dougherty & Co increased their price target on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. Omnicell presently has an average rating of “Buy” and a consensus price target of $54.86.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.